Healthcare Regulatory Monitoring in the United States

Healthcare is the most heavily regulated industry in the United States. Between the FDA approving and overseeing drugs and devices, CMS setting reimbursement policy for the $1.5 trillion Medicare program, HHS enforcing HIPAA privacy and security standards, and state boards licensing practitioners, compliance teams in healthcare organizations face a volume of regulatory output that exceeds any other sector. A single hospital system may need to track rulemaking from a dozen federal agencies and multiple state health departments — all publishing simultaneously on different schedules.

Key Regulatory Bodies

• Food and Drug Administration (FDA) — Oversees the safety and efficacy of drugs, biologics, medical devices, food, and tobacco products. The FDA publishes hundreds of guidance documents, approval decisions, warning letters, and recalls annually. Its regulatory scope covers everything from clinical trial requirements to post-market surveillance.
• Centers for Medicare & Medicaid Services (CMS) — Administers Medicare, Medicaid, and the ACA marketplace. CMS annual rulemaking on the Physician Fee Schedule, Hospital Outpatient Prospective Payment System, and Medicare Advantage directly determines reimbursement rates and coverage policies affecting every healthcare provider in the country.
• Office for Civil Rights (OCR) — Enforces HIPAA Privacy, Security, and Breach Notification rules. OCR has levied over $140 million in HIPAA penalties since the regulation's inception and significantly increased enforcement of the HIPAA Security Rule following a surge in healthcare data breaches.
• Office of Inspector General (OIG), HHS — Investigates fraud, waste, and abuse in federal healthcare programs. The OIG's annual Work Plan identifies compliance risk areas it will prioritize, and its enforcement actions under the False Claims Act have recovered billions in overpayments.
• Drug Enforcement Administration (DEA) — Regulates controlled substances, including prescribing, dispensing, and record-keeping requirements for healthcare providers handling Schedule II-V drugs. DEA's rules on telemedicine prescribing of controlled substances remain a moving target post-pandemic.

Critical Regulations

• HIPAA Privacy and Security Rules (45 CFR Parts 160, 164) — Establishes national standards for protecting patient health information. The proposed HIPAA Security Rule update, published in early 2025, would require multifactor authentication, network segmentation, and encryption for all ePHI — the most significant update to HIPAA security requirements since 2013.
• Stark Law (42 USC § 1395nn) and Anti-Kickback Statute — Prohibit physician self-referrals and the exchange of remuneration for referrals in federal healthcare programs. CMS and OIG regularly publish advisory opinions and special fraud alerts that shape how healthcare organizations structure compensation, joint ventures, and value-based care arrangements.
• No Surprises Act (2022) — Protects patients from unexpected out-of-network medical bills and establishes an independent dispute resolution process between providers and insurers. CMS continues to refine implementation rules, including provider directory accuracy requirements and good faith estimate obligations.
• FDA 21st Century Cures Act — Interoperability Rules — Requires healthcare IT developers to support standardized APIs (HL7 FHIR) for patient data access and prohibits information blocking. ONC enforces these requirements, with penalties for non-compliance increasing through 2026.
• CMS Hospital Price Transparency Rule — Requires hospitals to publish machine-readable files of negotiated rates for all items and services. CMS raised the maximum penalty to $5,500 per day for non-compliant hospitals and has progressively increased enforcement actions.

What You're Missing

• CMS annual rulemaking cycles drive operational changes. The Physician Fee Schedule proposed rule drops every July and finalizes in November, affecting billing codes, payment rates, and quality reporting requirements effective January 1. Missing the comment period means losing your chance to influence policy. Missing the final rule means scrambling to implement changes with weeks of lead time.
• FDA guidance documents often carry the weight of rules. The FDA issues draft and final guidances that, while technically non-binding, define how the agency evaluates compliance and makes enforcement decisions. A guidance on AI/ML-enabled medical devices or laboratory-developed tests can reshape an entire product strategy overnight.
• State-level healthcare regulation is accelerating. States are enacting their own health data privacy laws (Washington My Health My Data Act, Connecticut), pharmacy benefit manager regulations, and telehealth licensure compacts that create compliance obligations beyond federal requirements. Operating across state lines without monitoring each state's health department and legislature leaves significant gaps.

How RegPulse Helps

RegPulse monitors the FDA, CMS, OCR, OIG, DEA, ONC, and state health departments for healthcare-relevant publications. Track drug approvals and warning letters, CMS payment rule updates, HIPAA enforcement actions, OIG fraud alerts, and state-level health privacy laws — all in one dashboard. Filter by sub-sector (pharma, devices, digital health, provider operations) and get alerts when any agency publishes something that affects your compliance obligations, with a summary of what changed and what action is required.